OPTIMIZE
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 190 patients (estimated)
- Sponsors
- Center for International Blood and Marrow Transplant Research
- Collaborators
- National Marrow Donor Program (NMDP)
- Tags
- Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1747
- NCT Identifier
- NCT06001385
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.